BioSpace News Archive

Through ACC’s TRANSFORM program, three first-of-a-kind studies will apply implementation science to revolutionize care

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s first quarter 2021 financial results will be released before market open on Wednesday, May 5, 2021.

Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter financial results on Wednesday, May 5, 2021.

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Vivlion GmbH, a company providing next-generation CRISPR gRNA libraries and screening services for the global R&D market, today announced a collaboration for the generation of gRNA libraries for CRISPR applications.

Apollo Endosurgery, Inc. (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the first quarter ended March 31, 2021 on Tuesday, May 4, 2021 after the market closes. In conjunction with the release,

Ocular Innovations, a Division of Engage Technologies Group, Inc. today announced it has launched their comprehensive, Optometric-exclusive video content library tailored for the Optometry industry that optimizes the overall Ocular patient experience.

Enalare Therapeutics Inc. announced today that it has received an initial contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to support development of the company’s lead product ENA-001.

HealthMyne, a pioneer in applied radiomics, announced today that a recent scientific publication has validated the company’s technology as a radiomics tool to inform clinical decision-making, identify imaging biomarkers and predict tumor response to cancer treatment.

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has partnered with the Foundation for California Community Colleges to make COVID-19 testing available to the 116 California community colleges and their more than 2.1 million students.

Data evaluating intravenous delivery of the AAVrh.10 viral vector show effectiveness in providing high levels of gene transfer to the heart for the potential treatment of rare cardiac diseases Data on second generation investigational gene therapy demonstrate ability to silence the APOE4 gene for the potential treatment of Alzheimer’s disease Additional pre-clinical data on the company’s gene therapy technology platform will also be presented